Abstract: Glucagon-like peptide-1 (GLP-1) because of its hypoglycemic effect, brings a new occasion to the treatment of type 2 diabetes in clinical practice. Cardiovascular disease is a common complication of diabetes, the study found that GLP-1 and analogs can improve endothelial function, inhibit inflammation, reduce infarct size and ischemia/reperfusion injury, inhibition of cardiomyocyte apoptosis and improve myocardial energy metabolism.These roles can reduce the risk of cardiovascular disease and provide new ways and means for clinical treatment of cardiovascular diseases.

Key words: glucagon-like peptide-1, analogues, cardiovascular system, type 2 diabetes mellitus